Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Helen Timmis et al.|Cancer Research|2024Cited by 3
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Ana OrtegoFranco et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2